


Figure S1



**Figure S1. Related to Figures 1 and 2. Ba2017-EGFP localization 48-72 hours after injection.**

(A) Representative images of brainstem (left; including the DMV-dorsal motor nucleus of the vagus) and spinal cord (right; including the IML-intermediolateral nucleus) from *Ins1-Cre* mice 48 hours after viral injection ( $n = 2$ , 5 images per mouse). Ba2017-EGFP fluorescence, green. (Scale bar = 500 $\mu$ m) Dashed areas represent the regions of interest in green identified in the brain section micrographs next to each image.

(B) Representative images of pancreas sections from *Ins1-Cre* mice 48 hours after viral injection ( $n = 2$ , 4 images per mouse). Insulin antibody staining, magenta; Ba2017-EGFP fluorescence, green. (Scale bar = 500 $\mu$ m)

(C) Quantification of % of EGFP positive islets 24, 48 and 72 hours after Ba2017 injection ( $n = 2$  per time point).


(D) Representative images of pancreatic sections with EGFP<sup>+</sup> (green) and insulin (magenta) labeling from *Ins1-Cre* (top) and C57Bl6 (bottom) mice 72 hours after Ba2017 injection ( $n = 2$  mice per condition, 4 images per mouse). (Scale bar = 500 $\mu$ m)

(E) Representative images of pancreatic sections with EGFP<sup>+</sup> (green) and rb134 (magenta) labeling from *Ins1-Cre* (top) and C57Bl6 (bottom) mice 72 hours after Ba2017 injection ( $n = 2$  mice per condition, 4 images per mouse). (Scale bar = 500 $\mu$ m)

(F) Representative images of PVN and spinal cord sections with rb134 (magenta) labeling from *Ins1-Cre* (top) and C57Bl6 (bottom) mice 72 hours after Ba2017 injection ( $n = 2$  mice per condition, 4 images per mouse). (Scale bar = 200 $\mu$ m) Dashed areas represent the regions of interest in green identified in the brain section micrographs above each image.

All sections were counterstained with nuclear marker DAPI (blue).

Figure S2



**Figure S2. Related to Figure 2. Comparison of Ba2017 and Ba2001 neuronal tracing.**


(A) Representative images of pancreatic sections with GFP<sup>+</sup> (green) and insulin (magenta) immunostaining from *Ins1*-Cre mice 120h after injection with Ba2001 ( $n = 2$  mice per condition, 4 images per mouse). (Scale bar = 500 $\mu$ m).

(B) Representative images of IML with GFP<sup>+</sup> (green) and rb134 (magenta) immunostaining from *Ins1*-Cre mice 120h after injection with Ba2017 (top;  $n = 4$ , 4 images per mouse) or Ba2001 (bottom;  $n = 3$ , 4 images per mouse). (Scale bar = 200 $\mu$ m).

(C) Representative images of EGFP<sup>+</sup> (Ba2017) fluorescent labeling or GFP<sup>+</sup> (Ba2001) immunostaining in various brain regions 120 hours after Ba2017 (top;  $n = 4$ , 4-8 images per region per mouse) or Ba2001 (bottom;  $n = 3$ , 4-8 images per region per mouse) administration. (Scale bar = 200 $\mu$ m). Dashed areas represent the regions of interest in green identified in the brain section micrographs above each image.

IML=intermediolateral nucleus of the spinal cord, PVN=Paraventricular nucleus of the hypothalamus, LH= Lateral hypothalamus, VMH=Ventromedial hypothalamic nucleus, DMH= Dorsomedial hypothalamic nucleus, CeA= Central nucleus of the amygdala, PAG= Periaqueductal grey, PBN= Parabrachial nucleus, SubC= Subcoeruleus nucleus, DMV= Dorsal motor nucleus of the vagus, Aq= Aqueduct, 3V= 3<sup>rd</sup> Ventricle.

Figure S3




**Figure S3. Related to Figure 3. PVN Vasopressin co-labeling with EGFP 72 hours after injection and chemogenetic stimulation.**

(A) Representative image of  $\beta$ -cell-projecting PVN neurons expressing EGFP (green) and vasopressin (magenta) 72 hours after Ba2017 administration ( $n = 5$ , 4 images per mouse). Dashed square on upper left panel represents the area of the magnified image on the upper right panel. (Scale bar =  $50\mu\text{m}$ ).

(B) (Top) Schematic representation of DREADD virus injection site with representative image of viral mCherry expression in  $\text{PVN}^{\text{AVP}}$  neurons. (Bottom) Effect of  $\text{PVN}^{\text{AVP}}$  stimulation with CNO ( $0.5\text{mg/kg}$ ) during GSIS on 10-minute plasma insulin levels in  $\text{PVN}^{\text{AVP:hM3Dq}}$  mice ( $n = 5$ ).

Figure S4












**Figure S4. Related to Figure 3. Effect of PVN<sup>OXT</sup> neuron stimulation on glucagon and epinephrine levels and effect of SON<sup>OXT</sup> chemogenetic stimulation on insulin levels.**

(A-B) Effect of chemogenetic stimulation of PVN<sup>OXT</sup> neurons with CNO during GSIS on 10-minute plasma glucagon levels in mice injected with (A) hm3Dq ( $n = 7$ ) or (B) control ( $n = 4$ ) virus (mCherry). Graphs show mean  $\pm$  sem.

(C-D) Effect of chemogenetic stimulation of PVN<sup>OXT</sup> neurons with CNO during GSIS on 10-minute plasma epinephrine levels in mice injected with (C) hm3Dq ( $n = 7$ ) or (D) control ( $n = 4$ ) virus (mCherry). Graphs show mean  $\pm$  sem.

(E) (Left) Schematic representation of DREADD virus injection site with representative image of viral mCherry expression and (Right) SON<sup>OXT</sup> chemogenetic stimulation with CNO during GSIS on 10-minute plasma insulin levels ( $n = 4$ , 4 images per mouse). Graphs show mean  $\pm$  sem.

**Figure S5**





**Figure S5. Related to Figures 3 and 4. Effect of PVN<sup>OXT</sup> neuron stimulation on prandial glycemia.**

(A) Schematic representation of the feeding protocol followed for testing prandial glucose levels. Food was removed from cages at 2pm. Mice were injected with either saline or CNO (1mg/kg) at 5pm and food was reintroduced at 6pm. Values were normalized with the average of the one-hour period before food reintroduction.

(B-E) Experiments with PVN<sup>OXT:hM3Dq</sup> mice.

(B) Normalized glyceimic changes after injection of saline or CNO (1mg/kg) and during 1h post feeding. Glucose measurements inside the shaded area (1h post feeding, grey) were used for quantification of AUC and peak glyceimia (blue and green shaded areas represent respective error bars). Baseline glucose (average glucose levels from injection to food placement; time -60 to 0):  $85.77 \pm 5.150$  and  $85.27 \pm 9.189$  respectively ( $n = 4$ ). (C) Effect of CNO administration on prandial glyceimic AUC, and (D) peak glyceimia levels during the first 1h of feeding ( $n = 4$ )  $*P < 0.05$ ,  $***P < 0.001$ ; paired t-test. (E) Effects of chemogenetic stimulation of PVN<sup>OXT</sup> neurons on overnight food intake ( $n = 4$ ).

(F-I) Experiments with spPVN<sup>OXT:hM3Dq</sup> mice.

(F) Normalized glyceimic changes after injection of saline or CNO (1mg/kg) and during 1h post feeding. Glucose measurements inside the shaded area (1h post feeding, grey) were used for quantification of AUC and peak glyceimia (blue and green shaded areas represent respective error bars) Baseline glucose (average glucose levels from injection to food placement; time -60 to 0):  $121.3 \pm 7.596$  and  $127.2 \pm 6.563$  respectively ( $n = 5$ ). (G) Effect of CNO administration on prandial glyceimic AUC, and (H) peak glyceimia levels during the first 1h of feeding ( $n = 5$ )  $*P < 0.05$ ,  $**P < 0.01$ ; paired t-test. (I) Effects of chemogenetic stimulation of spPVN<sup>OXT</sup> neurons on overnight food intake ( $n = 5$ ).